Interstitial Cystitis Pipeline Summary

DelveInsight’s, “Interstitial Cystitis - Pipeline Insight, 2026” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Interstitial Cystitis: Understanding

Interstitial Cystitis: Overview

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition affecting the urinary bladder and is characterized by bladder or pelvic pain, pressure, or discomfort accompanied by lower urinary tract symptoms such as urinary urgency, frequency, and nocturia. Symptoms generally persist for more than 6 weeks and occur in the absence of urinary infection or another identifiable cause. Pain is often aggravated by bladder filling and may be temporarily relieved after urination.

The exact cause of IC/BPS remains unclear and is considered multifactorial. Proposed contributing factors include chronic inflammation, immune-mediated or autoimmune processes, mast-cell dysfunction, urothelial dysfunction, pelvic-floor abnormalities, neurogenic inflammation, fibrosis, and increased sensitivity of sensory nerves. Damage or dysfunction of the bladder's protective glycosaminoglycan (GAG) layer may also contribute to increased urothelial permeability and exposure of underlying tissues to urinary substances.

The pathophysiology of IC/BPS is complex and not completely understood. Dysfunction of the bladder urothelium, including thinning or loss of the protective GAG layer and abnormalities of tight and adhesive junctions, can impair the bladder's mucosal barrier and increase urothelial permeability. Chronic inflammation is associated with mast-cell activation, inflammatory-cell infiltration, and microvascular abnormalities. At the same time, increased sensory afferent nerve activity and nociceptor upregulation contribute

to bladder pain, while central nervous system sensitization can further amplify pain perception.

IC/BPS is primarily a diagnosis of exclusion because there is no single definitive diagnostic test. Diagnosis involves a detailed medical history and physical examination, assessment of urinary symptoms and pain, urinalysis, and urine culture to exclude infection and other conditions with similar presentations. Symptoms typically need to persist for at least 6 weeks with negative urine cultures and no alternative explanation. A 24-hour voiding diary and validated symptom or pain questionnaires may help assess disease severity. Cystoscopy and urodynamic testing are not routinely required but may be used when the diagnosis is uncertain or other disorders need to be excluded; cystoscopy may identify characteristic Hunner lesions in a subset of patients.

There is currently no single curative treatment for IC/BPS, so management is individualized and generally involves multimodal symptom control. Initial approaches include patient education, dietary modification, avoidance of bladder irritants, stress management, pelvic-floor relaxation, and manual physical therapy. Pharmacological treatment may include oral agents such as amitriptyline, pentosan polysulfate, hydroxyzine, cimetidine, or, in selected patients, cyclosporine A. Intravesical therapies can include dimethyl sulfoxide (DMSO), lidocaine or bupivacaine with sodium bicarbonate, heparin, and other agents. Patients with persistent symptoms may undergo cystoscopy with low-pressure hydrodistension and treatment of Hunner lesions, while refractory cases may be considered for botulinum toxin A, neuromodulation, or, as a last resort, surgery.

"Interstitial Cystitis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Cystitis pipeline landscape is provided which includes the disease overview and Interstitial Cystitis treatment guidelines. The assessment part of the report embraces, in depth Interstitial Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Cystitis.

Interstitial Cystitis Emerging Drugs Chapters

This segment of the Interstitial Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interstitial Cystitis Emerging Drugs

• VNX 001: Vaneltix Pharma, Inc./ Hyloris Pharmaceuticals

VNX001 is an intravesical therapeutic formulation combining alkalinized lidocaine hydrochloride and heparin sodium, designed to treat interstitial cystitis (IC)/bladder pain syndrome (BPS) by providing local anesthesia and bladder-lining protection to reduce bladder pain and urgency. The formulation is intended to act on two key aspects of IC/BPS: lidocaine provides local anesthetic activity to reduce bladder pain, while heparin is intended to provide a protective effect on the bladder urothelium and support the integrity of the bladder’s glycosaminoglycan (GAG) layer. Through these complementary effects, VNX001 is being evaluated for rapid reduction of acute bladder pain and other IC/BPS symptoms. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Interstitial Cystitis.

• GLX-100: Glycologix, Inc.

GLX-100 is a locally administered, synthetic glycosaminoglycan (GAG) biopolymer developed by Glycologix for interstitial cystitis/bladder pain syndrome (IC/BPS). It is designed to mimic the protective properties of naturally occurring proteoglycans and to replenish the defective GAG layer on the bladder surface. Following intravesical administration, GLX-100 binds to the bladder wall and forms a hydrated protective coating that restores bladder impermeability and helps prevent urinary solutes from penetrating the underlying tissue. By restoring the bladder’s natural protective barrier, GLX-100 is intended to reduce irritation and the downstream processes associated with IC/BPS symptoms such as bladder pain, urgency, and frequency. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Interstitial Cystitis.

Further product details are provided in the report……..

Interstitial Cystitis: Therapeutic Assessment

This segment of the report provides insights about the different Interstitial Cystitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Interstitial Cystitis

There are approx. 11+ key companies which are developing the therapies Interstitial Cystitis. The companies which have their Interstitial Cystitis drug candidates in the most advanced stage, i.e. Phase II include, Vaneltix Pharma, Inc., and others.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Cystitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Cystitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Cystitis drugs.

Interstitial Cystitis Report Insights

• Interstitial Cystitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interstitial Cystitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Interstitial Cystitis drugs?
• How many Interstitial Cystitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Cystitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interstitial Cystitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vaneltix Pharma, Inc.
• Hyloris Pharmaceuticals
• Glycologix
• Cyllene Therapeutics
• TAGCyx Biotechnologies
• Ono Pharmaceutical

Key Products

• V NX001
• GLX-100
• EG110A
• TAGX-0003
• ONO-1110